Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Newly Diagnosed Acute Myeloid Leukemia (AML): full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Newly Diagnosed Acute Myeloid Leukemia (AML): 2 US clinical trials tracked, none currently recruiting.
Newly Diagnosed Acute Myeloid Leukemia (AML) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Institut de Recherches Internationales Servier, running 2 of these trials.
Enrollment posture brief
Registry condition newly-diagnosed-acute-myeloid-leukemia-aml
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Newly Diagnosed Acute Myeloid Leukemia (AML) has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Newly Diagnosed Acute Myeloid Leukemia (AML) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Newly Diagnosed Acute Myeloid Leukemia (AML) is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Institut de Recherches Internationales Servier
NCT02632708
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Institut de Recherches Internationales Servier
NCT03173248
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Newly Diagnosed Acute Myeloid Leukemia (AML) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Newly Diagnosed Acute Myeloid Leukemia (AML) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Newly Diagnosed Acute Myeloid Leukemia (AML) page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Newly Diagnosed Acute Myeloid Leukemia (AML) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Institut de Recherches Internationales Servier sponsors the most Newly Diagnosed Acute Myeloid Leukemia (AML) trials on record, review their full trial history before evaluating a specific study. See Institut de Recherches Internationales Servier's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Newly Diagnosed Acute Myeloid Leukemia (AML) condition card totals 2 registered trials; most-linked intervention AG-120; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.